Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation

•Letermovir prevents csCMV in allogenic HCT pts at high and standard-risk for CMV.•Total cost of care was compared for letermovir prophylaxis versus preemptive therapy.•For high-risk pts, letermovir decreases total cost of care through day+180.•For standard-risk pts, letermovir reduces inpatient cost of care through day+180.•Standard-risk pts benefit from letermovir by lower input room and pharmacy costs.